PT - JOURNAL ARTICLE AU - Alexander S. Hatoum AU - Sarah M.C. Colbert AU - Emma C. Johnson AU - Spencer B. Huggett AU - Joseph D. Deak AU - Gita Pathak AU - Mariela V. Jennings AU - Sarah E. Paul AU - Nicole R. Karcher AU - Isabella Hansen AU - David A.A. Baranger AU - Alexis Edwards AU - Andrew Grotzinger AU - Substance Use Disorder Working Group of the Psychiatric Genomics Consortium AU - Elliot M. Tucker-Drob AU - Henry R. Kranzler AU - Lea K. Davis AU - Sandra Sanchez-Roige AU - Renato Polimanti AU - Joel Gelernter AU - Howard J. Edenberg AU - Ryan Bogdan AU - Arpana Agrawal TI - Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders AID - 10.1101/2022.01.06.22268753 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.06.22268753 4099 - http://medrxiv.org/content/early/2022/01/12/2022.01.06.22268753.short 4100 - http://medrxiv.org/content/early/2022/01/12/2022.01.06.22268753.full AB - Genetic liability to substance use disorders can be parsed into loci conferring general and substance-specific addiction risk. We report a multivariate genome-wide association study that disaggregates general and substance-specific loci for problematic alcohol use, problematic tobacco use, and cannabis and opioid use disorders in a sample of 1,025,550 individuals of European and 92,630 individuals of African descent. Nineteen loci were genome-wide significant for the general addiction risk factor (addiction-rf), which showed high polygenicity. Across ancestries PDE4B was significant (among others), suggesting dopamine regulation as a cross-trait vulnerability. The addiction-rf polygenic risk score was associated with substance use disorders, psychopathologies, somatic conditions, and environments associated with the onset of addictions. Substance-specific loci (9 for alcohol, 32 for tobacco, 5 for cannabis, 1 for opioids) included metabolic and receptor genes. These findings provide insight into the genetic architecture of general and substance-specific use disorder risk that may be leveraged as treatment targets.Competing Interest StatementDisclosure: Dr. Kranzler is a member of advisory boards for Dicerna Pharmaceuticals and Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; and a member of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. Drs. Kranzler and Gelernter are named as inventors on PCT patent application #15/878,640 entitled: "Genotype-guided dosing of opioid agonists," filed January 24, 2018.Funding StatementFunding: T32DA007261 (ASH), DA54869 (AA, JG, HE), DA54750 (AA, RB), K02DA32573 (AA), R21AA027827 (RB), K01DA51759 (ECJ), DP1DA54394 (SS-R), R01AA027522 (AE), F31AA029934 (SEP), R01MH120219 (EMTD, ADG), RF1AG073593 (EMTD, ADG), P30AG066614 (EMTD), P2CHD042849 (EMTD), R33DA047527 (RP, GAP), T32 AA028259 (JDD)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data Availability: The MVP publicly available summary statistics were obtained via an approved dbGaP application (phs001672.v4.p1). The authors thank Million Veteran Program (MVP) staff, researchers, and volunteers, who have contributed to MVP, and especially participants who previously served their country in the military and now generously agreed to enroll in the study. Information for Opioid use disorder and problematic alcohol use was taken from this dbGAP application (For details, see https://www.research.va.gov/mvp/ and Gaziano, J.M. et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70, 214-23 (2016)). This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration (VA) Cooperative Studies Program (CSP) award #G002. Publicly available summary statistics for alcohol dependence and cannabis use disorder were also taken from the psychiatric genomics consortium: https://www.med.unc.edu/pgc/. Publicly available summary statistics for smoking were taken from the authors of PMCID: PMC5882602 upon request and from the GSCAN consortium: https://conservancy.umn.edu/handle/11299/201564 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability: The MVP summary statistics were obtained via an approved dbGaP application (phs001672.v4.p1). The authors thank Million Veteran Program (MVP) staff, researchers, and volunteers, who have contributed to MVP, and especially participants who previously served their country in the military and now generously agreed to enroll in the study. (For details, see https://www.research.va.gov/mvp/ and Gaziano, J.M. et al. Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70, 214-23 (2016)). This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration (VA) Cooperative Studies Program (CSP) award #G002. Publicly available data were also taken from the psychiatric genomics consortium: https://www.med.unc.edu/pgc/, and the GSCAN consortium: https://conservancy.umn.edu/handle/11299/201564